| Literature DB >> 24973918 |
Seonmi Jo1, Oleg Yarishkin2, Yu Jin Hwang3, Ye Eun Chun4, Mijeong Park5, Dong Ho Woo6, Jin Young Bae7, Taekeun Kim6, Jaekwang Lee6, Heejung Chun6, Hyun Jung Park8, Da Yong Lee6, Jinpyo Hong6, Hye Yun Kim3, Soo-Jin Oh9, Seung Ju Park6, Hyo Lee6, Bo-Eun Yoon6, YoungSoo Kim3, Yong Jeong10, Insop Shim8, Yong Chul Bae7, Jeiwon Cho5, Neil W Kowall11, Hoon Ryu12, Eunmi Hwang6, Daesoo Kim13, C Justin Lee14.
Abstract
In Alzheimer's disease (AD), memory impairment is the most prominent feature that afflicts patients and their families. Although reactive astrocytes have been observed around amyloid plaques since the disease was first described, their role in memory impairment has been poorly understood. Here, we show that reactive astrocytes aberrantly and abundantly produce the inhibitory gliotransmitter GABA by monoamine oxidase-B (Maob) and abnormally release GABA through the bestrophin 1 channel. In the dentate gyrus of mouse models of AD, the released GABA reduces spike probability of granule cells by acting on presynaptic GABA receptors. Suppressing GABA production or release from reactive astrocytes fully restores the impaired spike probability, synaptic plasticity, and learning and memory in the mice. In the postmortem brain of individuals with AD, astrocytic GABA and MAOB are significantly upregulated. We propose that selective inhibition of astrocytic GABA synthesis or release may serve as an effective therapeutic strategy for treating memory impairment in AD.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24973918 DOI: 10.1038/nm.3639
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440